Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Italian institute to implement first BSD-2000/3D deep regional hyperthermia system

BSD Medical : 11 June, 2008  (Application Story)
Azienda Ospedaliera Istituti Ospitalieri Di Verona has awarded BSD Medical’s European distributor a contract to supply a BSD-2000/3D deep regional hyperthermia system.
The system will also feature a SigmaHyperplan hyperthermia treatment planning option and a BSD-500 local hyperthermia system.

The system will replace a BSD-2000 hyperthermia system operated since 1996 by the Institute and will be located in the Ospedale Borgo Trento in a special suite dedicated to hyperthermia treatments. The BSD-2000/3D, scheduled for delivery in August 2008, will be the first BSD-2000/3D in Italy and the fifteenth in Europe.

Dr Sergio Maluta, head of the Radiation Oncology Department at the Institute, said, 'We are pleased to further expand our activities in the field of clinical hyperthermia, the single most potent radiation sensitizer available. We are looking forward to close working relationships with all of the European Society for Hyperthermic Oncology, ESHO, member institutes in advancing hyperthermia cancer treatment.”

Ospedale Borgo Trento is one of the three hospitals that comprise the Azienda Ospedaliera Istituti Ospitalieri Di Verona, which also includes the medical school of the University of Verona. The Institute currently conducts more than 40,000 radiation treatments each year using five linear accelerators, one Gamma Knife and one IORT (intraoperative Radiotherapy treatment) unit. A

s a member of ESHO, the Institute participates in several major European clinical hyperthermia trials for the treatment of various cancerous tumours, including advanced prostate cancer, locally advanced as well as recurrent rectal cancer, advanced cervix cancer, bladder cancer, local breast wall recurrence and head and neck cancer. Dr Maluta will chair the 2009 Annual Meeting of the European Society for Hyperthermic Oncology in Verona.

The BSD-2000/3D employs three dimensional steering to deliver precision-focused RF energy into cancerous tumours, including those located deep in the body, raising the tumour temperature to levels required to administer hyperthermia therapy to destroy cancer cells with heat and increase the effectiveness of companion radiation therapy. Research has also shown promising results from the use of hyperthermia therapy in combination with some chemotherapy agents, and for tumour reduction prior to surgery.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo